Nearly 18 months after the US Food and Drug Administration (FDA) first acknowledged a national shortage of Adderall, the most common drug used to treat attention-deficit/hyperactivity […]

(Reuters) -Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative […]

The US Food and Drug Administration (FDA) has granted breakthrough designation to an LSD-based treatment for generalized anxiety disorder (GAD) based on promising topline data from […]

A large global report has found ongoing poor mental well-being worldwide, with no sign of improvement since prior to the COVID-19 pandemic. Published online on March […]

TOPLINE: Calls to US poison centers related to psilocybin more than tripled among teens and more than doubled in young adults between 2019 and 2022, new […]

TOPLINE: California wildfires are associated with a significant increase in psychotropic medication prescriptions — including those for antidepressants, anxiolytics, and mood stabilizers — for people living […]